The decrease in expenses was partially offset by an increase in costs related to patents, preclinical R&D activities, travel and consultants, and a decrease in grant participation by the Israel Innovation Authority, or IIA.

Aug 4, 2021 / receipt, needs a key / Dr. Preetam Shah, CFO | earnings call 2021-08-04 | transcript 5fbc81bb-4424-4246-bbce-9050207c0058 | chars 10694-10917 | segment 10

General and administrative expenses for the three months ended June 30, 2021, were $2.52 million compared to $1.71 million in the three months ended June 30, 2020. This increase of approximately $816,000 year over year was primarily due to an increase in payroll, stock-based compensation, consultants, rent, and other costs, partially offset by a decrease in PR and travel expenses.

Aug 4, 2021 / receipt, needs a key / Dr. Preetam Shah, CFO | earnings call 2021-08-04 | transcript 5fbc81bb-4424-4246-bbce-9050207c0058 | chars 11126-11509 | segment 11

This decrease of 1.61 million year-over-year was primarily due to decrease in expenses related to our Phase III and Phase II clinical trials and a decrease in expenses in connection with stock-based compensation, materials, travel, rent, and other activities.

Apr 25, 2021 / receipt, needs a key / Preetam Shah, CFO | earnings call 2021-04-25 | transcript 6be62983-8d90-44ae-9af2-371c4b38b631 | chars 11430-11689 | segment 11

This increase of $228,000 year-over-year was primarily due to increasing payroll, stock-based compensation, consultants, rent and other costs, partially offset by a decrease in PR and travel related expenses.

Apr 25, 2021 / receipt, needs a key / Stacy, other | earnings call 2021-04-25 | transcript 6be62983-8d90-44ae-9af2-371c4b38b631 | chars 12484-12692 | segment 12

This decrease year over year was primarily due to decrease in expenses related to the phase three and phase two clinical trials an increase in participation of IIA and CIRM under various awarded grants, and a decrease in expenses in connection with patents, travel, and other activities.

Oct 15, 2020 / receipt, needs a key / Preetam, CFO | earnings call 2020-10-15 | transcript adace4f2-7e3d-4dc5-b226-c5355f8b37cc | chars 15985-16272 | segment 15

This increase year-over-year was primarily due to an increase in payroll, stock-based compensation, PR costs, consultants, and other costs partially offset by decrease in travel expenses.

Oct 15, 2020 / receipt, needs a key / Preetam, CFO | earnings call 2020-10-15 | transcript adace4f2-7e3d-4dc5-b226-c5355f8b37cc | chars 16989-17176 | segment 16

This increase year-over-year was primarily due to increase in payroll, stock-based compensation, rent, and other costs partially offset by decrease in PR costs, consultants, and travel expenses.

Aug 5, 2020 / receipt, needs a key / Pritam Shah, CFO | earnings call 2020-08-05 | transcript 7ef704ff-9c0b-4ba7-bde9-b0d816b5f623 | chars 13647-13841 | segment 13

General and administrative expenses for the three months ended March 31, 2020 were $2.36 million compared to $1.47 million in the three months ended March 31, 2019. This increase year-over-year was primarily due to increase in payroll, stock-based compensation, PR and IR costs, rent, consultants, and travel.

May 7, 2020 / receipt, needs a key / Pritam Chow, CFO | earnings call 2020-05-07 | transcript 86aff417-8681-40b9-a07d-a3252921f398 | chars 9495-9804 | segment 9

A decrease of $1.5 million in proceeds received in connection with treatment of patients under the hospital exemption regulatory pathway, a decrease of approximately 2.6 million in participation of IIA and CIRM in 2020 under various awarded grants, and an increase of approximately 269,000 for costs related to travel, patents, and other costs.

Feb 3, 2020 / receipt, needs a key / Preetam Shah, CFO | earnings call 2020-02-03 | transcript d0d89e66-b6bc-49ca-9b43-d17937042fe9 | chars 11544-11888 | segment 11